Equity · Healthcare
Intuitive Surgical, Inc. (ISRG) perpetual futures
ISRG perpetual futures on 10 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade ISRGUSDT.
Intuitive Surgical develops and sells robotic surgical systems like the da Vinci and Ion, along with instruments and support services.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
10/10 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
10 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MEXC | Trade | ISRG/USDT | Trading | $400.37 | 0.0% APR 0.000% every 8h | +43.1 bps | $62.6K | $192.7K | $4.8M | USDT | 20x | |
XT.com | Trade | ISRG/USDT | Trading | $397.51 | 0.0% APR 0.000% every 8h | +13.8 bps | $57.4K | $145.2K | - | USDT | 25x | |
Bybit | Trade | ISRG/USDT | Trading | $397.62 | 0.0% APR 0.000% every 8h | +13.8 bps | $7.6K | $103.1K | $232.4K | USDT | 25x | |
HTX | Trade | ISRG/USDT | Trading | $397.60 | +11.0% APR +0.010% every 8h | +65.4 bps | $3.2K | $23.7K | $5.2K | USDT | - | |
Bitget | Trade | ISRG/USDT | Trading | $398.53 | 0.0% APR 0.000% every 8h | +3.8 bps | $153.1K | $20.8K | $122.2K | USDT | 20x | |
BingX | Trade | ISRG-USDT | Trading | $398.97 | -5.5% APR -0.00500% every 8h | +22.8 bps | $3.8K | $18.8K | $3.7K | USDT | - | |
OKX | Trade | ISRG/USDT | Trading | $398.51 | 0.0% APR 0.000% every 8h | +22.3 bps | $3.9K | $9K | $82.6K | USDT | 10x | |
Gate.io | Trade | ISRG/USDT | Trading | $398.70 | 0.0% APR 0.000% every 8h | +135.5 bps | $9.2K | $4.5K | $81.8K | USDT | 20x | |
Extended | Trade | ISRG/USD | Trading | $403.50 | +4.4% APR +0.00050% every 1h | +604.2 bps | - | $0 | $1.6K | USD | 10x | |
Helix (Injective) | Trade | ISRG/USDC | Trading | $401.83 | +3.6% APR +0.00042% every 1h | - | $0 | $0 | - | USDC | 12x |
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| ISRGxxStocks | $397.23 | -0.33% | $265 | $187k | Ethereum · Solana · BNB Smart Chain (BEP20) · Arbitrum |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kThin liquidity · 3 of 10 venues absorb $10k · Typical cost: +47.5 bps – +63.9 bps
Cheapest execution: XT.com · +43.5 bps
Too thin: Bybit, OKX, BingX, HTX
No fresh book data: Gate.io, Extended, Helix (Injective)
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
ISRGTightest spread
ISRGHighest volume
ISRGFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $484.87 |
| 12-month target range (low – high) | $357.44 – $558 |
| Ratings in the provider's consensus | 57 |
Price targets as of 2026-11-22
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 7 | 19 | 6 | 1 | 1 |
| Oct 2026 | 8 | 19 | 7 | 1 | 1 |
| Sep 2026 | 7 | 17 | 8 | 1 | 0 |
| Aug 2026 | 7 | 17 | 9 | 1 | 0 |
| Jul 2026 | 7 | 17 | 10 | 1 | 1 |
| Jun 2026 | 6 | 16 | 9 | 1 | 1 |
| May 2026 | 7 | 16 | 10 | 1 | 1 |
| Apr 2026 | 7 | 17 | 9 | 1 | 1 |
| Mar 2026 | 8 | 17 | 10 | 1 | 1 |
| Feb 2026 | 8 | 16 | 10 | 1 | 1 |
| Jan 2026 | 8 | 16 | 11 | 1 | 1 |
| Dec 2025 | 7 | 15 | 11 | 1 | 1 |
Ownership
Institutional · 2026-Q3Reference market activity
ISRG-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25Officer Brosius Mark sold 92 shares of Intuitive Surgical common stock in two open-market sales on Nov 19-20, 2026, at $407.24-$420.95, leaving 227 shares owned.
Intuitive Surgical officer Mark Brosius sold 138 common shares in three open-market sales on Nov 16-18, 2026, at $430.63-$444.38, leaving 319 shares owned.
Insider Loeb Gary (EVP & Chief Legal) sold 400 common shares for $458.15 each on Nov 10, 2026, leaving 6,236 shares directly held.
Director Gary S. Guthart sold 10,000 shares of Intuitive Surgical common stock on Nov 4, 2026, at $457.337 per share, leaving 1,194,530 shares owned.
Director Barratt exercised options on 1,150 shares at $90.49 and sold 1,150 common shares at $460.00.
Intuitive Surgical officer Brosius Mark sold 124 shares of common stock in two open-market transactions on Oct 29-30, 2026, at $447.85-$453.60, leaving 457 shares owned.
Intuitive Surgical officer Widman Fredrik exercised options (M-Exempt) on 13 tranches, acquiring 4,902 common shares at prices from $109.49 to $347.42 on 2026-10-30. No open-market purchases or sales were reported.
Filings
63 · Latest SEC filingsOfficer Brosius Mark sold 92 shares of Intuitive Surgical common stock in two open-market sales on Nov 19-20, 2026, at $407.24-$420.95, leaving 227 shares owned.
Intuitive Surgical officer Mark Brosius sold 138 common shares in three open-market sales on Nov 16-18, 2026, at $430.63-$444.38, leaving 319 shares owned.
Insider Loeb Gary (EVP & Chief Legal) sold 400 common shares for $458.15 each on Nov 10, 2026, leaving 6,236 shares directly held.
Director Gary S. Guthart sold 10,000 shares of Intuitive Surgical common stock on Nov 4, 2026, at $457.337 per share, leaving 1,194,530 shares owned.
Director Barratt exercised options on 1,150 shares at $90.49 and sold 1,150 common shares at $460.00.
Intuitive Surgical officer Widman Fredrik exercised options (M-Exempt) on 13 tranches, acquiring 4,902 common shares at prices from $109.49 to $347.42 on 2026-10-30. No open-market purchases or sales were reported.
Intuitive Surgical officer Brosius Mark sold 124 shares of common stock in two open-market transactions on Oct 29-30, 2026, at $447.85-$453.60, leaving 457 shares owned.
Intuitive Surgical officer Mark Brosius sold 183 common shares in three open-market sales on Oct 26-28, 2026 at $441.60-$451.75, leaving 581 shares owned.
Intuitive Surgical officer Fredrik Widman exercised 4,047 stock options (M-Exempt) into common shares and sold 4,047 common shares (S-Sale) on 2026-10-23.
Officer Patricia L. Wadros sold 1,078 common shares of Intuitive Surgical at $443.80 (S-Sale), leaving 0 shares owned after the transaction.
Director Gary S. Guthart reported an open-market sale (S-Sale) of 20,095 Intuitive Surgical common shares at $451.6117, leaving 1,204,530 shares owned.
Director Craig H. Barratt exercised 1,150 non-qualified stock options into 1,150 common shares at $90.4944 and sold those 1,150 shares on the open market at $443.80.
Intuitive Surgical officer Patricia L. Wadors converted 2,140 restricted stock units into 2,140 common shares (M-Exempt) on 2026-10-10, and 1,062 shares were withheld for taxes at $423.96 (F-InKind).
Intuitive Surgical officer Gary Loeb converted 2,612 restricted stock units into 2,612 common shares, and 1,296 shares were withheld for taxes at $423.96. He held 6,636 shares afterward.
Intuitive Surgical officer Fredrik Widman exercised 1,089 options (M-Exempt) into common stock at $79.64-$109.49 and sold 543 shares at $374.44.
Intuitive Surgical officer Mark Brosius reported selling 48 common shares in two open-market sales on Sep 10-11, 2026, at prices from $347.66 to $365.79; 764 shares remained after.
Intuitive Surgical officer Brosius Mark sold 69 common shares in two open-market sales on Sept 8-9, 2026 at $350.20-$361.23, leaving 812 shares held.
Brosius Mark, EVP at Intuitive Surgical, sold 154 common shares in two open-market transactions on Aug 20-21, 2026, at prices between $375.57 and $396.37.
Officer Mark Brosius sold a total of 231 common shares of Intuitive Surgical in three open-market transactions on Aug 17-19, 2026, at prices from $390.67 to $394.26 per share.
Director Gary S Guthart sold 10,000 common shares at $400 each on Aug 11, 2026, leaving 1,245,679 shares owned.
Director Amy L. Ladd sold 472 common shares of Intuitive Surgical in two open-market transactions on Aug 10-11, 2026, at prices ranging from $379 to $393.1 per share.
Gary Loeb, EVP & Chief Legal and Compliance Officer of Intuitive Surgical, sold 400 common shares at $379 each on August 10, 2026, retaining 5,320 shares.
Intuitive Surgical officer Mark Brosius sold 56 common shares over two open-market sales on July 30-31, 2026, at $346.83-$351, leaving 1,266 shares owned.
Mark Brosius (EVP & Chief Mfg and Supply Chain) sold 84 shares of Intuitive Surgical common stock across 3 trades at prices between $344 and $365.58, leaving 1,322 shares owned.
CEO Rosa David J. exercised 1,910 restricted stock units into 1,910 common shares on 2026-07-10; 947 shares were withheld for tax at $411.55. He held 246,856 shares after.
Mark Brosius (EVP & Chief Mfg and Supply Chain) sold 48 shares of Intuitive Surgical common stock on the open market over two transactions on 2026-06-11 and 2026-06-12, at prices between $412.16 and $414.13, leaving 1,406 shares owned afterward.
Intuitive Surgical CEO David J. Rosa exercised 1,358 RSUs into 1,358 common shares and had 674 shares withheld for taxes at $426.61. He held 245,893 shares after these transactions.
Intuitive Surgical officer Mark Brosius sold 69 common shares in 3 open-market sales on June 8-10, 2026 at $420.12-$424.14, leaving 1,454 shares owned.
Gary Loeb, EVP & Chief Legal and Compliance Officer of Intuitive Surgical, sold 400 shares of common stock at $424.14 on 2026-06-10, leaving 5,720 shares owned afterward.
Intuitive Surgical officer Jeddi Iman exercised 5,625 stock options at $76.9989 and sold 5,625 common shares at $420.55 on June 1, 2026, leaving 6,463 shares directly owned.
Intuitive Surgical officer Mark Brosius reported selling 36 common shares on May 21-22, 2026 at $439.80-$446.04, leaving 1,523 shares held.
Intuitive Surgical officer Mark Brosius reported selling 54 common shares in 3 open-market sales on May 18-20, 2026 at $422.47-$440.70, leaving 1,559 shares owned.
Gary Loeb, EVP & Chief Legal and Compliance Officer, sold 400 shares of Intuitive Surgical common stock at $446.95 per share, leaving him with 6,120 shares owned.
Director Gary Guthart received a grant of 554 Restricted Stock Units on 4/30/2026, a compensation award rather than an open-market purchase.
Craig H Barratt, a director, had 750 RSUs convert into 750 common shares, and separately received a new grant of 643 restricted stock units.
Director Joseph C Beery converted 531 RSUs into 531 common shares, and was awarded 554 new restricted stock units.
Director Lewis Chew converted 531 vested RSUs into 531 common shares and received a new award of 554 restricted stock units as compensation.
Director Amal M Johnson converted 531 restricted stock units into 531 shares of Intuitive Surgical common stock, now holding 13,545 shares directly.
Director Amy L. Ladd converted 531 RSUs into 531 common shares, and was separately awarded 554 new RSUs as compensation.
Director Monica P. Reed converted 531 RSUs into 531 common shares and received a new grant of 554 restricted stock units.
Director Kolli Sreelakshmi converted 531 RSUs into 531 common shares and received a new award of 554 RSUs.
Director Jami K. Nachtsheim had 531 RSUs convert into 531 common shares, and was granted 554 new restricted stock units as compensation.
Keith R. Leonard converted 531 RSUs into 531 common shares, and separately received a new grant of 554 RSUs as compensation. No shares were purchased on the open market.
Amy L. Ladd, a director at Intuitive Surgical, sold 619 shares of common stock total across two open-market sales on 2026-04-28 and 2026-04-29, at prices between $463.50 and $473.46 per share.
Myriam Curet exercised 105 stock options at $229.39, converting them into 105 common shares, then sold all 105 shares at $493.95.
Transcripts
Earnings callsFY2026 Q22026-07-16
Earnings calls
AI summary
mixedIntuitive Surgical delivered solid Q2 FY2026 results with total revenue of $2.89 billion, up 19%, and non-GAAP EPS of $2.80, up 28% year-over-year. Total procedures grew 16%, driven by da Vinci procedure growth of 15% and ION procedure growth of 36%. The company placed 468 da Vinci systems and 55 ION systems. However, US da Vinci procedure growth moderated to 12% in Q2 from 14% in Q1, primarily due to deferred procedures affected by ACA premium subsidy changes and patient coverage dynamics, though management believes underlying disease burden remains unchanged. International da Vinci procedures grew 20%, with strength in India, Europe, and Asia, offset by continued challenges in China. The company introduced over 100 planned updates to the da Vinci 5 platform and announced an extended use program beginning in H1 2027 for select ENDORIST instruments to reduce customer costs in benign procedures. Management maintained 2026 da Vinci procedure growth guidance of 13.5%-15.5% and updated non-GAAP gross margin guidance to 68%-69% from 67.5%-68.5%, reflecting tariff benefits and improved manufacturing efficiency partially offset by higher input costs.
Key takeaways
- US da Vinci procedure growth moderated to 12% in Q2 due to deferred procedures from ACA premium subsidy expiration and patient coverage changes, with management expecting procedures to resume when patients return to care
- Da Vinci 5 adoption accelerated with 246 of 468 placements, supported by first phase of 100+ planned platform updates focused on telepresence, simulation training, and care team workflow
- Extended use program launching in H1 2027 will increase useful lives of select ENDORIST instruments to lower customer costs in benign procedures, with full impact quantification deferred to next earnings call
- ION procedures reached 48,000 in Q2 with 36% growth, now exceeding 400,000 cumulative procedures, with commercial teams installed in 12 countries outside the US
Financial highlights
- Q2 revenue increased 19% to $2.89 billion, with recurring revenue up 19% to $2.47 billion representing 85% of total revenue
- Non-GAAP operating margin was 42%, and non-GAAP EPS increased 28% to $2.80 per share from $2.19 in Q2 prior year
- Non-GAAP gross margin improved to 70% from 67.9% prior year, including $36 million benefit from IEPA tariff refunds; excluding tariff benefit, adjusted margin was 68.7%
- Systems revenue grew 19% to $685 million with 468 da Vinci placements up 18% and Service revenue increased 21% to $472 million reflecting 12% growth in da Vinci installed base
Guidance
- 2026 da Vinci procedure growth maintained in range of 13.5%-15.5% with expectation to be closer to midpoint, factoring in ACA premium subsidy impacts, China tender volumes, and competitive pressures
- Non-GAAP gross profit margin updated to 68%-69% of revenue from prior 67.5%-68.5%, reflecting tariff benefits and product cost reductions offset by higher input costs in freight and semiconductors
- Non-GAAP operating expense growth expected between 11%-13% for 2026, with R&D growing faster than SG&A, and stock compensation expense estimated at $880-900 million
- Other income projected at $315-335 million for 2026, non-GAAP tax rate expected at 22%-23%, with no foundation contribution anticipated in 2026 versus $70 million multiyear contribution in Q4 2025
Q&A themes
- Management confirmed US da Vinci growth moderation driven by ACA subsidy expiration causing patient procedure deferrals in deferrable categories, with underlying disease burden unchanged and procedures expected to resume
- Extended use program details deferred pending internal analysis; company balancing growth opportunities in lower-acuity procedures with profitability and will provide quantification on next earnings call
- China market remains challenging with lower tender activity, increased domestic robotic competition, and policy-driven pricing pressure; new centralized tender process expected to reinforce need for strong robotic programs rather than system-specific customization
- Da Vinci 5 upgrade cycle characterized as progressive occurring over multiple years, with historical reference that Xi upgrade cycle took approximately 7 years to peak trade-in volumes
Risks
- US procedure growth moderation from ACA premium subsidy expiration and patient coverage dynamics creates uncertainty around procedure resumption timing, though management expects underlying disease burden will drive future treatment
- China operating environment remains challenging with lower tender volumes, competitive pricing pressure, and policy uncertainty including charge code changes and 5-year plan quota process, limiting near-term growth prospects
- Extended use program quantification not yet provided, creating modeling uncertainty regarding I&A per procedure impact in 2027-2028 as cost reductions may offset gains from da Vinci 5 and other higher-priced product mix
FY2026 Q12026-04-21
Earnings calls
AI summary
positiveIntuitive delivered solid Q1 2026 results with total procedures growing 17% (da Vinci +16%, Ion +39%), generating $2.77B in revenue with 39% non-GAAP operating margin. The company raised full-year 2026 da Vinci procedure growth guidance to 13.5%-15.5% from 13%-15% and gross margin guidance to 67.5%-68.5% from 67%-68%. Strategic investments in digital infrastructure, Force Feedback instrumentation, and geographic expansion are progressing, though China and Japan face near-term headwinds.
Key takeaways
- Q1 revenue grew 23% to $2.77B with recurring revenue representing 86% of total; non-GAAP operating margin strong at 39%
- Da Vinci 5 installed base reached ~1,500 systems with ~13,000 surgeons using it; da Vinci 5 utilization ~11% higher than Xi and trade-ins increased to 119 from 67 year-over-year
- Placed 431 da Vinci systems (17% increase) including 232 da Vinci 5 systems; placed 52 Ion systems with Ion procedures growing 39% and diagnostic yield of 79% per Mayo Clinic publication
- Force Feedback instruments achieved contribution margins comparable to Xi; five of six instruments now cleared for 15 uses after March 510(k) approval
- Single Port platform procedures grew 68% with U.S. utilization accelerating 22% year-over-year; SP stapler moved into broad U.S. launch and used in ~40% of expected cases
Financial highlights
- Q1 2026 revenue: $2.77B (+23% YoY); non-GAAP gross margin: 67.8% (vs. 66.4% prior year)
- Non-GAAP net income: $901M (+36% YoY); non-GAAP EPS: $2.50 vs. $1.81 prior year
- I&A revenue: $1.7B (+23%); da Vinci I&A revenue per procedure: $1,880 vs. $1,780 prior year
- Systems revenue: $651M (+24%); service revenue: $434M (+19%); da Vinci leasing: 56% of placements
Guidance
- FY2026 da Vinci procedure growth: 13.5%-15.5% (raised from 13%-15%)
- FY2026 non-GAAP gross margin: 67.5%-68.5% (raised from 67%-68%), reflecting 100 basis points tariff impact
- FY2026 non-GAAP operating expense growth: 11%-14%; stock compensation: $890M-$920M
- FY2026 other income (primarily interest): $315M-$335M; non-GAAP effective tax rate: 22%-23%
Q&A themes
- AI and digital roadmap progressing through layered capabilities starting with high-quality data, moving to anatomy identification and augmented dexterity with automation; Force Feedback and da Vinci 5 provide differentiated data advantages
- Appendectomy emerging as opportunity with encouraging clinical outcomes vs. laparoscopy; Japan reimbursement expansion for 7 new procedures effective June 2026 expected to have modest impact with adoption taking time to develop
- Innovation-led revenue growth explained as accretive pricing for differentiated products (da Vinci 5, SP) balanced with cost-sensitive markets; revenue growth expected to continue outpacing procedure growth
- Competitive positioning emphasizing total program value over price point; refurbished Xi and tiered portfolio provide segmentation advantages; telesurgery and cardiac surgery on roadmap as longer-term opportunities
Risks
- China remains challenging with low tender activity, domestic competition, and pricing pressure; Japan capital placements remain below historical levels though recent policy support encouraging
- Macro headwinds including tariffs (100 bps impact), higher input costs (freight, semiconductor memory), and oil/memory prices expected to have greater unfavorable impact in remainder of year
- Cybersecurity incident in Q1 involving unauthorized access to customer and employee data; incident contained with no significant business/manufacturing disruption but cybersecurity protocols being strengthened
FY2025 Q42026-01-22
Earnings calls
AI summary
positiveIntuitive achieved $10.1B in 2025 revenue with 3.1M total procedures performed globally, driven by da Vinci 5 adoption, single-port platform momentum (87% growth), and Ion expansion (51% growth). The company received FDA clearance for cardiac procedures on da Vinci 5 and expanded into additional indications including nipple-sparing mastectomy. For 2026, the company expects da Vinci procedures to grow 13-15%, gross margins of 67-68%, and operating expense growth of 11-15%.
Key takeaways
- da Vinci procedures grew 18% globally in 2025 to 3.1M; single-port procedures grew 87% and Ion grew 51%
- FDA cleared cardiac procedures on da Vinci 5; company launching measured rollout with training support and plans to develop cardiac-specific instrumentation
- Placed 1,721 da Vinci systems in 2025 including 870 da Vinci 5 systems; launched 42 refurbished Xi systems (XiR) for ASC and international expansion
- 2026 guidance: da Vinci procedures 13-15% growth, gross margin 67-68%, operating expenses up 11-15%; expects 120 basis points tariff impact
Financial highlights
- 2025 revenue grew 21% to $10.1B; pro forma operating margin 37%, up 70 basis points despite tariff impact
- Q4 2025 revenue $2.87B, up 19%; pro forma EPS $2.53 vs $2.21 in Q4 2024; free cash flow $2.5B, up from $1.3B in 2024
- Recurring revenue 81% of total at $2.3B in Q4; da Vinci leasing revenue up 34%; service revenue up 21%
- Pro forma gross margin 67.8% in Q4 2025 vs 69.5% in Q4 2024; impacted by 95 basis points from tariffs and product mix
Guidance
- 2026 da Vinci procedure growth expected 13-15%, considering ACA premium subsidy changes, Medicaid funding, China competition, Japan capital challenges, and obesity management drugs
- 2026 gross profit margin guidance 67-68% of net revenue; tariff impact estimated at 1.2% plus or minus 10 basis points
- 2026 pro forma operating expense growth 11-15%; stock compensation expense estimated $890-920M; other income $355-375M
- 2026 pro forma effective tax rate estimated 22-23%; no longer providing specific capital expenditure guidance as capex expected to return to normalized levels
Q&A themes
- Cardiac surgery represents 160,000 procedures per year opportunity for da Vinci 5 globally; requires multiyear investments in training, cardiac-specific instrumentation, and digital tools
- ASC expansion opportunity focused on higher-volume centers with soft tissue procedures (cholecystectomy, hernia, GYN); 70% of ASC opportunity in IDN-affiliated centers where surgeons already trained on da Vinci
- Advanced imaging capabilities in development including new fluorescence molecules and hyperspectral imaging for tissue oxygenation; expected to create new revenue streams
- China competition intensified in Q4 with provincial tenders favoring local suppliers; 273 systems remain in current quota; company competing on pricing while maintaining healthy margins
Risks
- 2026 guidance reflects risk from potential ACA premium subsidy changes, Medicaid funding pressure, and macroeconomic capital constraints in Europe and Japan
- China market shows intensifying competition from local robotic companies with similar architectures; Q4 tender win ratio lower than prior year
- Tariff impact expected to increase from 65 basis points in 2025 to 120 basis points in 2026; da Vinci 5 still below target product costs affecting gross margins
FY2025 Q32025-10-21
Earnings calls
AI summary
positiveQ3 2025 delivered strong results with total revenue of $2.51 billion (23% growth) and pro forma operating margin of 39%. Da Vinci procedure growth accelerated to 19% while ION procedures surged 52%, reflecting broad adoption of da Vinci V and increased system utilization. The company raised full-year da Vinci procedure growth guidance and improved gross margin outlook.
Key takeaways
- Total procedure growth of 20% driven by 19% da Vinci growth and 52% ION growth; da Vinci V procedures reached 67,000 in Q3 vs 50,000 in Q2
- Da Vinci V installed base grew to 929 systems with 240 placements in Q3; 141 trading/upgrade transactions primarily from US customers switching to latest technology
- System utilization increased: da Vinci +4%, SP +35%, ION +14%; US da Vinci utilization grew 2% reflecting higher mix of da Vinci V systems
- Raised 2025 da Vinci procedure growth guidance to 17-17.5% from 15.5-17%; improved pro forma gross margin guidance to 67-67.5% from 66-67%
- ION procedures increased 52% to 38,000; da Vinci SP procedures grew 91% with 30 system placements; refurbished XI program launched with 20 systems sold to date
Financial highlights
- Q3 revenue: $2.51 billion (+23% YoY); pro forma operating margin: 39%; pro forma EPS: $2.40 per share (+30% YoY)
- Recurring revenue grew 21% to represent 85% of total revenue; systems revenue grew 33% to $590 million; service revenue grew 20% to $396 million
- INA revenue grew 20% to $1.5 billion; da Vinci INA revenue per procedure: ~$1,800 (flat); ION INA revenue per procedure: ~$2,200
- Da Vinci installed base increased 13% to 10,800 systems; ION installed base grew 30% to 950 systems; leasing represented 54% of da Vinci placements
Guidance
- 2025 da Vinci procedure growth: 17-17.5% (raised from 15.5-17%)
- 2025 pro forma gross margin: 67-67.5% of revenue (raised from 66-67%); tariff impact estimated at 70 basis points +/- 10 basis points
- 2025 pro forma operating expense growth: 11-13%; pro forma effective tax rate: 21-22%; capital expenditures: $625-675 million
- Other income (mostly interest): $350-360 million; stock compensation: $785-795 million
Q&A themes
- US da Vinci procedure acceleration in Q3 (16% growth) attributed to strong benign general surgery growth and potential acceleration from July-August elective procedure pull-ahead due to Medicare funding uncertainty
- Da Vinci V design delivering on intent with higher utilization; efficiency gains and integrated features like insufflation driving adoption; approximately 90% of da Vinci V procedures used integrated insufflation technology
- XI systems being redeployed to alternative sites (ASCs) within hospital networks with consistent user interfaces and interchangeable instruments enabling flexibility for customers; da Vinci V and XI capable of working together in integrated programs
- Bariatric procedures declining mid to high single digits for six quarters due to GLP-1 drug impact; surgeons cannot yet predict trajectory change; China environment remains constrained with slow tenders and competitive pricing pressure
Risks
- Bariatric procedure declines persisting for six quarters with unclear inflection point as GLP-1 drugs create uncertain dynamics in surgeon practices
- China market remains constrained and competitive with local preference dynamics; price pressure continues on both capital and INA sides
- OUS da Vinci utilization approximately 20% below US levels; Japan procedure growth below expectations due to lower capital placements and government budget challenges
FY2025 Q22025-07-22
Earnings calls
AI summary
positiveIntuitive delivered strong Q2 2025 results with 21% revenue growth, 17% da Vinci procedure growth, and 39% pro forma operating margin. The company placed 395 systems including 180 da Vinci 5 units during broad U.S. launch and raised full-year da Vinci procedure growth guidance to 15.5%-17%. International markets faced continued budget pressures, while da Vinci 5 features like force feedback showed early clinical promise and improved utilization metrics versus prior platforms.
Key takeaways
- Da Vinci 5 broad U.S. launch underway with 180 systems placed in Q2, bringing installed base to 689; trade-ins increased to 83 from 21 year-ago as customers upgrade
- Pro forma operating margin of 39% with 21% revenue growth; gross margin guidance updated to 66-67% of revenue reflecting tariff impacts of ~100 bps for full year
- Da Vinci procedure growth guidance raised to 15.5%-17% for FY2025; U.S. placements up 45% YoY driven by da Vinci 5 adoption, offset by international challenges in Japan, China, and Europe
- Early clinical evidence emerging on da Vinci 5 force feedback reducing complications and improving efficiency by up to 20% on certain procedures; capacity constraints on force feedback instruments expected through Q1 2026
- SP procedure growth accelerated to 88% YoY with 112% growth in Korea; Ion procedures grew 52% to ~35,000 with first commercial placements in Australia and Korea
Financial highlights
- Q2 2025 revenue $2.44B (+21% YoY); pro forma net income $798M vs. $641M prior year; pro forma EPS $2.19 (+23% YoY)
- Pro forma gross margin 67.9% vs. 70.0% prior year, down from higher facilities costs, da Vinci 5 and Ion mix, and tariff impact of ~60 bps in quarter
- Da Vinci installed base grew 14% to 10,500 systems; average system utilization up 2% YoY; da Vinci 5 average selling price $1.5M vs. $1.44M prior year
- Operating cash flow positive; cash and investments $9.5B (+$400M sequentially); share repurchases of $181M (350K shares at $518/share average)
Guidance
- FY2025 da Vinci procedure growth guidance: 15.5%-17% (raised from 15-17%); reflects China uncertainty, OUS budget pressures, and continued bariatric procedure declines
- Pro forma gross margin FY2025: 66-67% of revenue (updated from 65-66.5%); tariff impact estimated at ~100 bps +/- 20 bps assuming 30% China import rate and 10% other rates
- Pro forma operating expense growth FY2025: 10-14%; stock compensation $770-790M; other income $370-390M; tax rate 22-23%
- Capital expenditures FY2025: $650-725M for facility construction including Bulgaria manufacturing site opened in Q2
Q&A themes
- Force feedback instrument supply constraints expected through Q1 2026; early evidence building on value for outcomes and surgeon learning curve, with capacity expansion underway
- Reprocessed/remanufactured third-party instruments: company emphasizes hospital value committees will evaluate safety, performance, reliability, supply continuity against cost savings; plans continued innovation and cost reduction
- Medicaid coverage uncertainty: ~70-80M Americans affected; Intuitive's relative penetration lower in Medicaid vs. other coverage types; younger Medicaid demographic may support adoption if economic/clinical value demonstrated
- Da Vinci 5 international expansion planned as measured rollout in Europe and Japan following CE Mark and regulatory clearances; force feedback instruments not expected cleared in Europe before end of 2026
Risks
- International macro headwinds in Japan, China, and Europe from government budget constraints and trade uncertainties; tariff environment dynamic with potential for incremental impact beyond current 100 bps estimate
- Force feedback instrument supply constrained through Q1 2026, limiting near-term penetration of this key da Vinci 5 differentiator in core procedures
- Bariatric procedure declines continuing at similar rates; potential loss of Medicaid coverage for 70-80M Americans could reduce hospital admissions and capital budgets
FY2025 Q12025-04-22
Earnings calls
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.No articles from Reuters, WSJ, Bloomberg or FT for this company in our feed.
Company data
Company intelligence
Updated: Nov 21, 2026, 09:06 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Chief executive
- David J. Rosa
- Employees
- 17,021
- IPO date
- Jun 16, 2000
- Country
- US
- Exchange
- NASDAQ Global Select
Rating factors
- Return on equityi
- 5/5
- Return on assetsi
- 5/5
- Debt to equityi
- 1/5
- Price to earningsi
- 1/5
- Price to booki
- 1/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VOO | 0.23% | 9.4M |
| VTI | 0.21% | 8.9M |
| QQQ | 0.72% | 7.6M |
| IVV | 0.24% | 4.8M |
| XAW.TO | 0.14% | 4.8M |
| XSP.TO | 0.25% | 4.8M |
| SPY | 0.24% | 4.4M |
| FXAIX | 0.22% | 4.3M |
| VUG | 0.46% | 3.9M |
| VGHAX | 2.9% | 2.7M |
| XLV | 2.27% | 2.6M |
| VIIIX | 0.23% | 1.9M |
Analyst track record
How the analysts covering ISRG have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 156 | 468 |
| Analysts | 34 | 38 |
| Buy / hold / sell | 136 / 19 / 1 | 396 / 68 / 4 |
| Upgrades / downgrades / initiations | 6 / 2 / 4 | 10 / 5 / 5 |
| Price targets hit / missed | 4 / 137 (3%) | 30 / 381 (7%) |
| Avg. return after a rating (TipRanks) | -25.1% | -22.4% |
| Best / worst call | +11.3% / -45.7% | +23.4% / -45.7% |
After buy calls on this stock: median 21-day move +1.8% vs S&P 500 +1.4% (n = 416)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Ryan ZimmermanBTIG94% hit rate on this stock · 31 targets measuredBuytarget $513Nov 18, 2026
- Larry BiegelsenWells Fargo75% hit rate on this stock · 24 targets measuredBuytarget $486Oct 21, 2026
- Mike KratkyLeerink Partners71% hit rate on this stock · 14 targets measuredBuytarget $503Oct 21, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 18, 2026 | Ryan ZimmermanBTIGNov 18, 2026 | BuyMaintained | $513↗ | article ↗ |
| Nov 17, 2026 | Vik ChopraBMO CapitalNov 17, 2026 | BuyMaintained | $518↗ | article ↗ |
| Nov 9, 2026 | Travis SteedBank of America SecuritiesNov 9, 2026 | BuyMaintained | $500↗ | article ↗ |
| Oct 21, 2026 | Travis SteedBank of America SecuritiesOct 21, 2026 | BuyReiterated | $470↗ | article ↗ |
| Oct 21, 2026 | Mike KratkyLeerink PartnersOct 21, 2026 | BuyReiterated | $503↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 156 ratings
Frequently asked questions
Where can I trade ISRG perpetual futures?
Intuitive Surgical, Inc. (ISRG) perpetual futures trade on 10 crypto venues, including MEXC, XT.com, Bybit. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade ISRG around the clock?
Yes. Unlike the underlying stock, ISRG perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on ISRG perpetuals?
Right now the ISRG perp funding rate is 0.0% annualized (venue median), ranging from -5.5% to +11.0% across 10 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the ISRG perp price compare to the Intuitive Surgical, Inc. stock?
The venue-median ISRG perp mark is $398.6 versus a reference stock price of $398.5, a basis of 0.0%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a ISRG perpetual future?
A ISRG perpetual is a derivative that tracks the price of Intuitive Surgical, Inc. with no expiry date. It lets you take long or short exposure to Intuitive Surgical, Inc. on crypto venues, around the clock.
What is ISRGUSDT perpetual?
ISRGUSDT is the symbol most crypto exchanges use for the Intuitive Surgical, Inc. perpetual settled in USDT (Tether). It tracks the ISRG share price through an index, trades 24/7 with leverage and never expires.
MEXC
XT.com
Bybit
HTX
Bitget
BingX
OKX
Gate.io
Extended
Helix (Injective)